Ethyl Loflazepate (International)
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
N05BA18
CAS registry number (Chemical Abstracts Service)
0029177-84-2
Chemical Formula
C18-H14-Cl-F-N2-O3
Molecular Weight
361
Therapeutic Category
Anxiolytic agent
Chemical Name
1H-1,4-Benzodiazepin-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, etyl ester
Foreign Names
- Ethylis loflazepas (Latin)
- Ethyl loflazepat (German)
- Loflazépate d'éthyle (French)
- Loflazepato de etilo (Spanish)
Generic Names
- Ethyl Loflazepate (OS: JAN)
- Loflazépate d'éthyle (OS: DCF)
- CM 6912 (Sanofi) (IS)
Brand Names
- Demethox
Nichi-Iko Pharmaceutical, Japan - Ethyl Loflazepate Sawai
Sawai Seiyaku, Japan - Ethyl Loflazepate Towa
Towa Yakuhin, Japan - Meilax
Meiji, China; Meiji Seika Pharma, Japan - Meilax 1%
Meiji Seika Pharma, Japan - Ronlax
Shiono Kemikaru, Japan - Sukarnase
Towa Yakuhin, Japan - Victan
Sanofi, Dominican Republic; Sanofi, Guatemala; Sanofi, Panama; Sanofi Belgium, Belgium; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, France; Sanofi-Aventis, Honduras; Sanofi-Aventis, Mexico; Sanofi-Aventis, Portugal; Sanofi-Aventis, Paraguay; Sanofi-Aventis, El Salvador; Sintofarm, Romania - Victan 2mg
Sanofi Belgium, Luxembourg
Glossary
Term | Definition |
---|---|
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
JAN | Japanese Accepted Name |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.